CN1551795A - 从血液中去除代谢组分 - Google Patents
从血液中去除代谢组分 Download PDFInfo
- Publication number
- CN1551795A CN1551795A CNA028173619A CN02817361A CN1551795A CN 1551795 A CN1551795 A CN 1551795A CN A028173619 A CNA028173619 A CN A028173619A CN 02817361 A CN02817361 A CN 02817361A CN 1551795 A CN1551795 A CN 1551795A
- Authority
- CN
- China
- Prior art keywords
- blood
- blood plasma
- plasma
- barrier
- electrophoresis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008280 blood Substances 0.000 title claims abstract description 340
- 210000004369 blood Anatomy 0.000 title claims abstract description 337
- 230000002503 metabolic effect Effects 0.000 title abstract 3
- 238000001962 electrophoresis Methods 0.000 claims abstract description 196
- 230000004888 barrier function Effects 0.000 claims abstract description 54
- 230000005684 electric field Effects 0.000 claims abstract description 27
- 238000009826 distribution Methods 0.000 claims abstract description 21
- 238000001816 cooling Methods 0.000 claims abstract description 20
- 210000002381 plasma Anatomy 0.000 claims description 188
- 238000000034 method Methods 0.000 claims description 156
- 238000000502 dialysis Methods 0.000 claims description 80
- 230000008569 process Effects 0.000 claims description 80
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims description 54
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims description 54
- 239000007788 liquid Substances 0.000 claims description 44
- 229910019142 PO4 Inorganic materials 0.000 claims description 41
- 239000010452 phosphate Substances 0.000 claims description 41
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 40
- 210000003734 kidney Anatomy 0.000 claims description 34
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 25
- 230000004060 metabolic process Effects 0.000 claims description 25
- 239000004202 carbamide Substances 0.000 claims description 23
- 238000013508 migration Methods 0.000 claims description 22
- 230000005012 migration Effects 0.000 claims description 22
- 238000001631 haemodialysis Methods 0.000 claims description 20
- 230000004087 circulation Effects 0.000 claims description 17
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 14
- 229940116269 uric acid Drugs 0.000 claims description 14
- 238000002347 injection Methods 0.000 claims description 13
- 239000007924 injection Substances 0.000 claims description 13
- 239000002699 waste material Substances 0.000 claims description 13
- 230000009931 harmful effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 229920002401 polyacrylamide Polymers 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 7
- 238000009434 installation Methods 0.000 claims description 6
- 238000005086 pumping Methods 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 4
- 239000007789 gas Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 239000012809 cooling fluid Substances 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 31
- 239000011148 porous material Substances 0.000 abstract 4
- 210000001367 artery Anatomy 0.000 description 54
- 206010018910 Haemolysis Diseases 0.000 description 43
- 229920000669 heparin Polymers 0.000 description 43
- 230000008588 hemolysis Effects 0.000 description 42
- 239000007853 buffer solution Substances 0.000 description 40
- 241001494479 Pecora Species 0.000 description 38
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 34
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 32
- 239000000306 component Substances 0.000 description 32
- 230000000694 effects Effects 0.000 description 31
- 229960002897 heparin Drugs 0.000 description 31
- 238000002474 experimental method Methods 0.000 description 30
- 238000012545 processing Methods 0.000 description 30
- 238000012360 testing method Methods 0.000 description 26
- 241001465754 Metazoa Species 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 238000009792 diffusion process Methods 0.000 description 17
- 238000005516 engineering process Methods 0.000 description 17
- 239000012530 fluid Substances 0.000 description 17
- 239000000463 material Substances 0.000 description 17
- 239000003792 electrolyte Substances 0.000 description 16
- 238000005070 sampling Methods 0.000 description 16
- 235000002639 sodium chloride Nutrition 0.000 description 16
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 15
- 230000017531 blood circulation Effects 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 210000000440 neutrophil Anatomy 0.000 description 15
- 238000011160 research Methods 0.000 description 15
- 229910052708 sodium Inorganic materials 0.000 description 15
- 239000011734 sodium Substances 0.000 description 15
- 102100022133 Complement C3 Human genes 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000002441 uremic toxin Substances 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 12
- 102000009027 Albumins Human genes 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 11
- 102000006395 Globulins Human genes 0.000 description 10
- 108010044091 Globulins Proteins 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 239000003053 toxin Substances 0.000 description 9
- 231100000765 toxin Toxicity 0.000 description 9
- 108700012359 toxins Proteins 0.000 description 9
- 208000037157 Azotemia Diseases 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000008103 glucose Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 208000009852 uremia Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 239000000385 dialysis solution Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- -1 phosphate anion Chemical class 0.000 description 7
- 229910052698 phosphorus Inorganic materials 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 206010015548 Euthanasia Diseases 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 6
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 6
- 102100033467 L-selectin Human genes 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- 101000833181 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Glycerol dehydrogenase 1 Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 229920002239 polyacrylonitrile Polymers 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 5
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 238000005054 agglomeration Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000005611 electricity Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 229920002492 poly(sulfone) Polymers 0.000 description 5
- 239000011591 potassium Substances 0.000 description 5
- 229910052700 potassium Inorganic materials 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- JOJMQRPFXIKGJG-UHFFFAOYSA-N acetic acid;carbonic acid Chemical compound CC(O)=O.OC(O)=O JOJMQRPFXIKGJG-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 208000020832 chronic kidney disease Diseases 0.000 description 4
- 230000024203 complement activation Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000003344 environmental pollutant Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 230000002969 morbid Effects 0.000 description 4
- 230000035479 physiological effects, processes and functions Effects 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- 231100000719 pollutant Toxicity 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 3
- VJRLOPVXROQXLO-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;urea Chemical compound NC(N)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VJRLOPVXROQXLO-BTVCFUMJSA-N 0.000 description 3
- 102000004411 Antithrombin III Human genes 0.000 description 3
- 108090000935 Antithrombin III Proteins 0.000 description 3
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 229920001503 Glucan Polymers 0.000 description 3
- 206010059484 Haemodilution Diseases 0.000 description 3
- 206010019663 Hepatic failure Diseases 0.000 description 3
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
- 102100032999 Integrin beta-3 Human genes 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102100030859 Tissue factor Human genes 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 229960005348 antithrombin iii Drugs 0.000 description 3
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 208000007903 liver failure Diseases 0.000 description 3
- 231100000835 liver failure Toxicity 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- AXSWDVPMPIZVKD-UHFFFAOYSA-L potassium sodium hydrogen carbonate chloride Chemical compound [Na+].[Cl-].[K+].OC([O-])=O AXSWDVPMPIZVKD-UHFFFAOYSA-L 0.000 description 3
- 230000026676 system process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QGVLYPPODPLXMB-UBTYZVCOSA-N (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-4a,7b,9,9a-tetrahydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-1,1a,1b,4,4a,7a,7b,8,9,9a-decahydro-5H-cyclopropa[3,4]benzo[1,2-e]azulen-5-one Chemical compound C1=C(CO)C[C@]2(O)C(=O)C(C)=C[C@H]2[C@@]2(O)[C@H](C)[C@@H](O)[C@@]3(O)C(C)(C)[C@H]3[C@@H]21 QGVLYPPODPLXMB-UBTYZVCOSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 201000002980 Hyperparathyroidism Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010053159 Organ failure Diseases 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003251 chemically resistant material Substances 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 201000000523 end stage renal failure Diseases 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000008713 feedback mechanism Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000001473 noxious effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 2
- QGVLYPPODPLXMB-QXYKVGAMSA-N phorbol Natural products C[C@@H]1[C@@H](O)[C@]2(O)[C@H]([C@H]3C=C(CO)C[C@@]4(O)[C@H](C=C(C)C4=O)[C@@]13O)C2(C)C QGVLYPPODPLXMB-QXYKVGAMSA-N 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004926 polymethyl methacrylate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000022558 protein metabolic process Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000011012 sanitization Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- HNGIZKAMDMBRKJ-UHFFFAOYSA-N 2-acetamido-3-(1h-indol-3-yl)propanamide Chemical compound C1=CC=C2C(CC(NC(=O)C)C(N)=O)=CNC2=C1 HNGIZKAMDMBRKJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 102000006996 Aryldialkylphosphatase Human genes 0.000 description 1
- 108010008184 Aryldialkylphosphatase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000017234 Bone cyst Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 108010077840 Complement C3a Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241000393496 Electra Species 0.000 description 1
- 206010016803 Fluid overload Diseases 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 229920002145 PharMed Polymers 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 208000005250 Spontaneous Fractures Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 206010060872 Transplant failure Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- NFXWJYUDIOHFAW-UHFFFAOYSA-N acetic acid;tetradecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCC(O)=O NFXWJYUDIOHFAW-UHFFFAOYSA-N 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 108010075226 adenovirus factor PL Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- ASARMUCNOOHMLO-WLORSUFZSA-L cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2s)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O ASARMUCNOOHMLO-WLORSUFZSA-L 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 230000037360 nucleotide metabolism Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 238000002616 plasmapheresis Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000003303 reheating Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 208000028528 solitary bone cyst Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000004781 supercooling Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 239000010891 toxic waste Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/42—Electrodialysis; Electro-osmosis ; Electro-ultrafiltration; Membrane capacitive deionization
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/42—Electrodialysis; Electro-osmosis ; Electro-ultrafiltration; Membrane capacitive deionization
- B01D61/425—Electro-ultrafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1601—Control or regulation
- A61M1/1603—Regulation parameters
- A61M1/1605—Physical characteristics of the dialysate fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
- A61M1/3623—Means for actively controlling temperature of blood
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D57/00—Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C
- B01D57/02—Separation, other than separation of solids, not fully covered by a single other group or subclass, e.g. B03C by electrophoresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0496—Urine
- A61M2202/0498—Urea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/15—Detection of leaks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3317—Electromagnetic, inductive or dielectric measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3324—PH measuring means
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3344—Measuring or controlling pressure at the body treatment site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3368—Temperature
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Water Supply & Treatment (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Electrochemistry (AREA)
- Environmental & Geological Engineering (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
- Electrostatic Separation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPR7485A AUPR748501A0 (en) | 2001-09-04 | 2001-09-04 | Renal dialysis |
AUPR7485 | 2001-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1551795A true CN1551795A (zh) | 2004-12-01 |
Family
ID=3831435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA028173619A Pending CN1551795A (zh) | 2001-09-04 | 2002-09-04 | 从血液中去除代谢组分 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1434645A4 (ja) |
JP (1) | JP4181038B2 (ja) |
CN (1) | CN1551795A (ja) |
AU (1) | AUPR748501A0 (ja) |
WO (1) | WO2003020403A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985822A (zh) * | 2010-06-28 | 2013-03-20 | 塔林科技大学 | 用于确定生物流体中的中分子和蛋白结合尿毒症毒素的含量的方法和装置 |
CN104404008A (zh) * | 2014-12-10 | 2015-03-11 | 辽宁省海洋水产科学研究院 | 一种海胆多功能肌动蛋白的分离纯化方法 |
CN104902940A (zh) * | 2012-12-20 | 2015-09-09 | 弗雷森纽斯医疗护理德国有限责任公司 | 血液透析过滤方法 |
CN104968377A (zh) * | 2013-01-04 | 2015-10-07 | 费森尤斯医疗德国有限公司 | 使用高频电磁场和静电直流场从患者血液中去除蛋白结合的毒素的装置和方法 |
CN109358105A (zh) * | 2018-09-26 | 2019-02-19 | 陕西绿盾环境工程研究院有限公司 | 一种减少春雷霉素残渣中春雷霉素含量装置及方法 |
CN110817802A (zh) * | 2019-10-24 | 2020-02-21 | 邯郸钢铁集团有限责任公司 | 一种利用复合纯化工艺制取超纯氢的系统及方法 |
CN111407943A (zh) * | 2020-04-25 | 2020-07-14 | 宁波高新区零零七工业设计有限公司 | 一种病毒吸附分离无害化处理设备及其处理方法 |
CN113181458A (zh) * | 2021-04-22 | 2021-07-30 | 浙大宁波理工学院 | 人工肝的生物反应器 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006126618A1 (ja) * | 2005-05-26 | 2006-11-30 | Signpost Corporation | 疾患危険度判定用遺伝子多型の決定方法、疾患危険度判定方法及び判定用アレイ |
JP4947693B2 (ja) * | 2006-07-14 | 2012-06-06 | 学校法人北里研究所 | アルブミンとアルブミンに結合した生体分子の分離方法 |
EP2087916A1 (en) | 2008-02-11 | 2009-08-12 | ICinnovation BV | Electrosorption device for the purification of blood and other fluids |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
EP2446908B1 (en) | 2010-11-02 | 2015-07-15 | ICinnovation BV | Electrosorption and decomposition device for the purification of blood and other fluids |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
DE102011078695A1 (de) | 2011-07-05 | 2013-01-10 | Charité - Universitätsmedizin Berlin | Dialyseverfahren zur Entfernung proteingebundener Toxine aus dem Blut von Patienten unter Einsatz hochfrequenter elektromagnetischer Felder |
ES2478695B1 (es) * | 2012-12-20 | 2015-04-28 | Servicio Andaluz De Salud | Dispositivo para inducir hipotermia terapéutica |
DE102012025164A1 (de) * | 2012-12-21 | 2014-06-26 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Entfernung proteingebundener Toxine aus Blutplasma |
EP2862584B1 (en) | 2013-10-21 | 2019-03-20 | ICinnovation BV | Electrosorption and decomposition device for the purification of blood and other fluids |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
KR102155857B1 (ko) | 2013-12-09 | 2020-09-15 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화 관련 질환들의 치료를 위한 방법 및 조성물 |
KR101552519B1 (ko) | 2014-05-13 | 2015-09-14 | 계명대학교 산학협력단 | 심혈관 질환 예방을 위한 지방 분리 시스템 및 지방 분리 방법 |
EA035799B1 (ru) | 2015-05-18 | 2020-08-12 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением |
EP4014984A1 (en) | 2015-06-15 | 2022-06-22 | The Board of Trustees of the Leland Stanford Junior University | Compositions for use in treating aging-associated conditions |
IL277205B (en) * | 2018-08-17 | 2022-07-01 | Univ Washington | Device and method for the photo-oxidation of urea |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3870617A (en) * | 1971-03-30 | 1975-03-11 | Rhone Poulenc Sa | Apparatus for forced flow electrophoresis |
US3989613A (en) * | 1973-05-16 | 1976-11-02 | The Dow Chemical Company | Continuous balanced flow fixed boundary electrophoresis |
US4276140A (en) * | 1980-01-10 | 1981-06-30 | Ionics Inc. | Electrodialysis apparatus and process for fractionating protein mixtures |
FR2568485B1 (fr) * | 1984-08-06 | 1990-03-23 | Rhone Poulenc Rech | Appareil de fractionnement par electrophorese de solutions contenant des proteines, utilisable notamment pour le fractionnement du plasma humain |
JPS62172965A (ja) * | 1986-01-27 | 1987-07-29 | 日東電工株式会社 | 血液処理装置 |
AUPP576598A0 (en) * | 1998-09-07 | 1998-10-01 | Life Therapeutics Limited | Cassette for macromolecule purification |
-
2001
- 2001-09-04 AU AUPR7485A patent/AUPR748501A0/en not_active Abandoned
-
2002
- 2002-09-04 CN CNA028173619A patent/CN1551795A/zh active Pending
- 2002-09-04 EP EP02759922A patent/EP1434645A4/en not_active Withdrawn
- 2002-09-04 JP JP2003524705A patent/JP4181038B2/ja not_active Expired - Fee Related
- 2002-09-04 WO PCT/AU2002/001217 patent/WO2003020403A1/en active IP Right Grant
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102985822A (zh) * | 2010-06-28 | 2013-03-20 | 塔林科技大学 | 用于确定生物流体中的中分子和蛋白结合尿毒症毒素的含量的方法和装置 |
CN104902940B (zh) * | 2012-12-20 | 2017-03-15 | 弗雷森纽斯医疗护理德国有限责任公司 | 血液透析过滤方法 |
US10172994B2 (en) | 2012-12-20 | 2019-01-08 | Fresenius Medical Care Deutschland Gmbh | Hemodiafiltration method |
CN104902940A (zh) * | 2012-12-20 | 2015-09-09 | 弗雷森纽斯医疗护理德国有限责任公司 | 血液透析过滤方法 |
US9682181B2 (en) | 2013-01-04 | 2017-06-20 | Fresenius Medical Care Deutschland Gmbh | Device and method for removing protein-bound toxins from the blood of patients using a high-frequency, electromagnetic field and an electrostatic direct current field |
CN104968377B (zh) * | 2013-01-04 | 2017-03-15 | 费森尤斯医疗德国有限公司 | 使用高频电磁场和静电直流场从患者血液中去除蛋白结合的毒素的装置和方法 |
CN104968377A (zh) * | 2013-01-04 | 2015-10-07 | 费森尤斯医疗德国有限公司 | 使用高频电磁场和静电直流场从患者血液中去除蛋白结合的毒素的装置和方法 |
CN104404008A (zh) * | 2014-12-10 | 2015-03-11 | 辽宁省海洋水产科学研究院 | 一种海胆多功能肌动蛋白的分离纯化方法 |
CN109358105A (zh) * | 2018-09-26 | 2019-02-19 | 陕西绿盾环境工程研究院有限公司 | 一种减少春雷霉素残渣中春雷霉素含量装置及方法 |
CN109358105B (zh) * | 2018-09-26 | 2021-01-05 | 陕西绿盾环境工程研究院有限公司 | 一种减少春雷霉素残渣中春雷霉素含量装置及方法 |
CN110817802A (zh) * | 2019-10-24 | 2020-02-21 | 邯郸钢铁集团有限责任公司 | 一种利用复合纯化工艺制取超纯氢的系统及方法 |
CN111407943A (zh) * | 2020-04-25 | 2020-07-14 | 宁波高新区零零七工业设计有限公司 | 一种病毒吸附分离无害化处理设备及其处理方法 |
CN113181458A (zh) * | 2021-04-22 | 2021-07-30 | 浙大宁波理工学院 | 人工肝的生物反应器 |
Also Published As
Publication number | Publication date |
---|---|
EP1434645A4 (en) | 2006-12-13 |
JP4181038B2 (ja) | 2008-11-12 |
WO2003020403A1 (en) | 2003-03-13 |
AUPR748501A0 (en) | 2001-09-27 |
EP1434645A1 (en) | 2004-07-07 |
JP2005527247A (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1551795A (zh) | 从血液中去除代谢组分 | |
US7066900B2 (en) | Removal of metabolic components from blood | |
RU2694327C2 (ru) | Способ культивирования в системе посевных ферментеров (варианты) | |
CN1407853A (zh) | 对流体进行生物修饰的装置及方法 | |
CN1122719C (zh) | 经修饰的生物材料 | |
CN1842589A (zh) | 用于从组织分离并且浓缩再生细胞的系统和方法 | |
US4963236A (en) | Apparatus and methods for isoelectric focusing | |
CN1259975C (zh) | 透析器的再生方法和装置 | |
CN1468138A (zh) | 多口分离装置及方法 | |
US20220267712A1 (en) | Cell isolation for use in automated bioreactors | |
EP3442688A1 (en) | Perfusion filtration systems | |
CN1871058A (zh) | 利用激光操纵进行基于多层流的颗粒和细胞分离 | |
CN1303201C (zh) | 从体积较大的样品中制备要分析的样品 | |
CN1473067A (zh) | 综合分离方法 | |
Morii et al. | Roles of MITF for development of mast cells in mice: effects on both precursors and tissue environments | |
US20060131236A1 (en) | Model for microfiltration of poly-disperse suspensions | |
Gramer et al. | Comparison of cell growth in T-flasks, in micro hollow fiber bioreactors, and in an industrial scale hollow fiber bioreactor system | |
EP3806973B1 (en) | Assembly with plate settler, and bottom section for connection thereto | |
RU2710967C2 (ru) | Способ отъемно-доливной ферментации с высокой плотностью клеток | |
CN1482939A (zh) | 用于分离分子和流体运动的设备和方法 | |
CN113980814B (zh) | 一种用于外周血红细胞快速裂解的组合物及其应用 | |
CN101031311A (zh) | 免疫增强剂及其生成方法和生成装置 | |
WO1995008105A1 (en) | Method for obtaining a cell population enriched in stem cells and compositions derived therefrom | |
CN1056261A (zh) | 多功能自由电泳技术 | |
RU2786997C2 (ru) | Процессы культивирования в системе посевных ферментеров и способы их применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20041201 |